Close Menu

NEW YORK (GenomeWeb) – Evercore ISI said today that it has initiated coverage of Twist Bioscience with an Outperform rating and a price target of $30.50.

In a note to investors, Evercore ISI Analyst Ross Muken and colleagues wrote that Twist can likely maintain a growth rate of more than 25 percent over the next three to five years through its DNA synthesis and NGS tools businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.